Cardiac-dose model validated non-cancer death risk in one lung SBRT cohort
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Tag
nsclc
Immune-sparing lung SBRT planning reduced lymphocyte loss in a randomized phase II trial
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
ESTRO defines clinical standards for high-dose thoracic reirradiation in NSCLC
ESTRO recommends selective high-dose thoracic reirradiation with comprehensive staging, limited target volumes and formal cumulative dose assessment.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
Consolidative and salvage primary-tumour SABR showed similar outcomes in stage IV NSCLC
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
Carbon ions triggered distinct cell-cycle and chromatin transcriptional responses
At equal physical dose, carbon ions produced transcriptional changes distinct from X-rays, including stronger suppression of mitotic and chromatin-regulatory programmes.
Durvalumab improved 2-year progression-free survival after chemoradiotherapy in real-world stage III NSCLC
Consolidation durvalumab after concurrent chemoradiotherapy halved the adjusted risk of progression or death at two years in real-world stage III NSCLC.
Lung SBRT studies use inconsistent definitions of local control
Nearly one-third of lung SBRT studies counted failures beyond the treated tumor as local events, limiting comparison of reported control rates.
Prophylactic cranial irradiation outperformed magnetic resonance imaging surveillance in limited-stage small cell lung cancer
Prophylactic cranial irradiation was associated with longer survival and brain metastasis-free survival than magnetic resonance imaging surveillance.
Artificial intelligence surrogate estimated coronary artery dose in lung stereotactic body radiotherapy
An artificial intelligence coronary artery surrogate strongly correlated with manual dose metrics in simulated lung stereotactic body radiotherapy.
Carbon ion radiotherapy yielded 82.9% two-year locoregional control in stage III non-small cell lung cancer
Carbon ion radiotherapy achieved 82.9% two-year locoregional control, while combined immunotherapy was associated with longer overall survival.
Prolonged pembrolizumab was associated with longer survival after chemoradiation in non-small cell lung cancer
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.